Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-33-2015 | Award Amount: 30.12M | Year: 2016
The vision of EU-ToxRisk is to drive a paradigm shift in toxicology towards an animal-free, mechanism-based integrated approach to chemical safety assessment. The project will unite all relevant disciplines and stakeholders to establish: i) pragmatic, solid read-across procedures incorporating mechanistic and toxicokinetic knowledge; and ii) ab initio hazard and risk assessment strategies of chemicals with little background information. The project will focus on repeated dose systemic toxicity (liver, kidney, lung and nervous system) as well as developmental/reproduction toxicity. Different human tiered test systems are integrated to balance speed, cost and biological complexity. EU-ToxRisk extensively integrates the adverse outcome pathway (AOP)-based toxicity testing concept. Therefore, advanced technologies, including high throughput transcriptomics, RNA interference, and high throughput microscopy, will provide quantitative and mechanistic underpinning of AOPs and key events (KE). The project combines in silico tools and in vitro assays by computational modelling approaches to provide quantitative data on the activation of KE of AOP. This information, together with detailed toxicokinetics data, and in vitro-in vivo extrapolation algorithms forms the basis for improved hazard and risk assessment. The EU-ToxRisk work plan is structured along a broad spectrum of case studies, driven by the cosmetics, (agro)-chemical, pharma industry together with regulators. The approach involves iterative training, testing, optimization and validation phases to establish fit-for-purpose integrated approaches to testing and assessment with key EU-ToxRisk methodologies. The test systems will be combined to a flexible service package for exploitation and continued impact across industry sectors and regulatory application. The proof-of-concept for the new mechanism-based testing strategy will make EU-ToxRisk the flagship in Europe for animal-free chemical safety assessment.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SFS-07b-2015 | Award Amount: 9.01M | Year: 2016
This aim of IMAGE is to enhance the use of genetic collections and to upgrade animal gene bank management. IMAGE will better exploit DNA information and develop methodologies, biotechnologies, and bioinformatics for rationalising animal genetic resources. It will demonstrate the benefits brought by gene banks to the development of sustainable livestock systems by: enhancing the usefulness of genetic collections to allow the livestock sector to respond to environment and market changes; using latest DNA technology and reproductive physiology for collecting, storing and distributing biological resources; Minimising genetic accidents such as abnormalities or genetic variability tipping points; Developing synergies between ex-situ and in-situ conservation to maximise resources for the future. To this end, the project will involve stakeholders, SME, and academic partners to achieve the following objectives. At the scientific level, the project will: Assess the diversity available in genetic collections; Search for adaptive traits through landscape genetics in local populations; Contribute to elucidate local populations and major genes history; Identify detrimental variants that can contribute to inbreeding depression; Predict cryobank samples reproductive performance; Facilitate the use of collections for genome-assisted breeding. At the technological level, it will develop: Procedures for harmonising gene bank operations and rationalising collections; Conservation and reproductive biotechnologies; A central information system to connect available data on germplasm and genomic collections. At the applied level, it will develop methods and tools for stakeholders to: Restore genetic diversity in livestock populations; Create or reconstruct breeds fitting new environmental constraints and consumer demands; Facilitate cryobanking for local breeds; Define and track breed-based product brands; Implement access and benefit sharing regulations.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC1-PM-01-2016 | Award Amount: 15.04M | Year: 2017
The complex interactions between genetic and non-genetic factors produce heterogeneities in patients as reflected in the diversity of pathophysiology, clinical manifestations, response to therapies, disease development and progression. Yet, the full potential of personalized medicine entails biomarker-guided delivery of efficient therapies in stratified patient populations. MultipleMS will therefore develop, validate, and exploit methods for patient stratification in Multiple Sclerosis, a chronic inflammatory disease and a leading causes of non-traumatic disability in young adults, with an estimated cost of 37 000 per patient per year over a duration of 30 years. Here we benefit from several large clinical cohorts with multiple data types, including genetic and lifestyle information. This in combination with publically available multi-omics maps enables us to identify biomarkers of the clinical course and the response to existing therapies in a real-world setting, and to gain in-depth knowledge of distinct pathogenic pathways setting the stage for development of new interventions. To create strategic global synergies, MultipleMS includes 21 partners and covers not only the necessary clinical, biological, and computational expertise, but also includes six industry partners ensuring dissemination and exploitation of the methods and clinical decision support system. Moreover, the pharmaceutical industry partners provide expertise to ensure optimal selection and validation of clinically relevant biomarkers and new targets. Our conceptual personalized approach can readily be adapted to other immune-mediated diseases with a complex gene-lifestyle background and broad clinical spectrum with heterogeneity in treatment response. MultipleMS therefore goes significantly beyond current state-of-the-art thereby broadly affecting European policies, healthcare systems, innovation in translating big data and basic research into evidence-based personalized clinical applications.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: EINFRA-22-2016 | Award Amount: 3.00M | Year: 2017
The goal of AARC2 is to design an AAI framework to develop interoperable AAI, to enable researchers to access the whole research and infrastructure service portfolio with one login. AARC2s objectives are: 1. enable federated access in research communities participating in AARC2 2. assist research communities to map their requirements to concrete service offerings 3. support research (e-)infrastructures to implement the integrated architecture and policies frameworks developed by AARC project 4. offer different trainings to adopt AARC/AARC2 results 5. enhance the integrated architecture AARC2 objectives will be achieved by: - Piloting selected research community use-cases (SA1) - Showcasing ready-to-use AAI solutions and pilot results to infrastructures (SA1-NA2) - Developing a virtual Competence Centre where infrastructure representatives and AARC2 team discuss AARC2 results deployment and approaches to use-cases (all WPs) - Promoting federated access and adoption of AARC2 results via training and outreach (NA2) - Expand support for new technologies and policies (JRA1 and NA3). - Follow a user-driven approach: development driven by use-cases and continuous community feedback on AARC2 work. Relevance to the work programme: - AARC2 will work with existing e-infrastructures and ESFRI projects to deploy and enhance (JRA1) the integrated AAI (built on eduIGAIN and federated access) delivered by AARC (obj1Development of a pan-European identity federation) - Use-cases that meet integration (accessing services offered by multiple e-infrastructures) and data-rich aspects included in AARC2 (SA1). AARC2 will work to enable federated access and to map the use-cases to existing AAI services and policy frameworks (obj2Stimulate AAI services supporting communities in the data-rich era) - AARC2 will liaise with security groups, NRENs and infrastructures to address best practices in cybersecurity and assurance (see NA3). (obj3Deliver an integrated infrastructure)
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC1-PM-22-2016 | Award Amount: 15.59M | Year: 2016
ZIKAlliance is a multidisciplinary project with a global One Health approach, built: on a multi-centric network of clinical cohorts in the Caribbean, Central & South America; research sites in countries where the virus has been or is currently circulating (Africa, Asia, Polynesia) or at risk for emergence (Reunion Island); a strong network of European and Brazilian clinical & basic research institutions; and multiple interfaces with other scientific and public health programmes. ZIKAlliance will addrees three key objectives relating to (i) impact of Zika virus (ZIKV) infection during pregnancy and short & medium term effects on newborns, (ii) associated natural history of ZIKV infection in humans and their environment in the context of other circulating arboviruses and (iii) building the overall capacity for preparedness research for future epidemic threats in Latin America & the Caribbean. The project will take advantage of large standardised clinical cohorts of pregnant women and febrile patients in regions of Latin America and the Caribbean were the virus is circulating, expanding a preexisting network established by the IDAMS EU project. I will also benefit of a very strong expertise in basic and environmental sciences, with access to both field work and sophisticated technological infrastructures to characterise virus replication and physiopathology mechanisms. To meet its 3 key objectives, the scientific project has been organised in 9 work packages, with WP2/3 dedicated to clinical research (cohorts, clinical biology, epidemiology & modeling), WP3/4 to basic research (virology & antivirals, pathophysiology & animal models), WP5/6 to environmental research (animal reservoirs, vectors & vector control) , WP7/8 to social sciences & communication, and WP9 to management. The broad consortium set-up allow gathering the necessary expertise for an actual interdisciplinary approach, and operating in a range of countries with contrasting ZIKV epidemiological status.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: INFRADEV-04-2016 | Award Amount: 9.95M | Year: 2017
The EOSCpilot project will support the first phase in the development of the European Open Science Cloud (EOSC) as described in the EC Communication on European Cloud Initiatives . It will establish the governance framework for the EOSC and contribute to the development of European open science policy and best practice; It will develop a number of pilots that integrate services and infrastructures to demonstrate interoperability in a number of scientific domains; and It will engage with a broad range of stakeholders, crossing borders and communities, to build the trust and skills required for adoption of an open approach to scientific research . These actions will build on and leverage already available resources and capabilities from research infrastructure and e-infrastructure organisations to maximise their use across the research community. The EOSCpilot project will address some of the key reasons why European research is not yet fully tapping into the potential of data. In particular, it will: reduce fragmentation between data infrastructures by working across scientific and economic domains, countries and governance models, and improve interoperability between data infrastructures by demonstrating how data and resources can be shared even when they are large and complex and in varied formats, In this way, the EOSC pilot project will improve the ability to reuse data resources and provide an important step towards building a dependable open-data research environment where data from publicly funded research is always open and there are clear incentives and rewards for the sharing of data and resources.
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: INFRADEV-03-2016-2017 | Award Amount: 4.97M | Year: 2017
The INFRAFRONTIER RI integrates European Mouse Clinics and the European Mouse Mutant Archive with the common goal to ensure access to mouse models for basic research of human health and disease, and to translate this knowledge into therapeutic approaches for the benefit of the European society. The expanded INFRAFRONTIER2020 network, coordinated by the INFRAFRONTIER GmbH, includes 3 SMEs and is strategically responding to the INFRADEV3 call with aligned objectives to advance the long-term sustainability which are 1) development of business models and a stable legal framework; 2) raise awareness of the INFRAFRONTIER RI; 3) provide bespoke services aligned with user demands; 4) promote best practices in mouse phenogenomics; 5) enhance robustness of the INFRAFRONTIER IT infrastructure and use of the EMMA strain resource; and 6) improve business processes. Towards achieving these objectives key INFRAFRONTIER2020 project deliverables are: INFRAFRONTIER Business Plan2.0, and business models for all services Stable legal framework built on the INFRAFRONTIER legal entity INFRAFRONTIER annual stakeholder conferences Customised mouse model and secondary phenotyping pilot services INFRAFRONTIER advanced training schools in mouse phenogenomics Reengineered EMMA Database2.0 system Annotated mouse models of human diseases Quality management system for the legal entity INFRAFRONTIER2020 will 1) enhance the sustainable operation of the INFRAFRONTIER RI; 2) continue to structure the ERA, 3) foster innovation, and 4) address major societal challenges in human health by customised service pilots supporting research into common and rare diseases. A sustainable INFRAFRONTIER RI will ensure the quality of deposited mice and support the reproducibility of biological results. Outreach efforts will raise awareness of resources and services and facilitate sustainable engagement with industry and global consortia such as the International Mouse Phenotyping Consortium